Replies to post #389797 on Amarin Corp Plc (AMRN)

[rosemountbomber]

So Kiwi how much do you think Amarin is making as a profit per bottle under that type of arrangement? I would guess a tad or hair more than the Generics although the Generics have really no incremental cost to add GV to their list of products that they distribute.

[ziploc_1]

KIWI...This is an interesting proposition...

QUOTE..."The rebates are to the large healthcare providers like Kaiser ….It’s a volume discount with a commitment purchase"....i.e. We ( Kaiser ) will purchase ( as example ) 100,000 bottles of Vascepa (1 mth supply per bottle ) for 2022 as long as it’s at least 1 c lower per bottle then the cost of the generic option"

Could this be the basis of a deal with China, which has a very large population, which could benefit from Vascepa?....i.e. We will give a very cheap price in return for enormous volume...As J.T. was wont to say...Vascepa is a volume play...not a price play.

Also. if China agreed on such deal, Amarin could then lower its prices for Vascepa in Europe and the U.S.